background
acut
respiratori
infect
ari
lead
caus
morbid
mortal
worldwid
need
demonstr
clinic
impact
use
new
rapid
sensit
molecular
assay
prospect
design
studi
object
studi
impact
medic
manag
rapid
molecular
assay
patient
respiratori
infect
studi
design
prospect
random
nonblind
studi
perform
patient
present
emerg
depart
two
respiratori
season
diagnosi
perform
filmarray
respiratori
panel
filmarrayrp
immunofluoresc
assay
ifa
result
total
patient
children
adult
analyz
diagnosi
filmarrayrp
associ
signific
chang
medic
manag
includ
withhold
antibiot
prescript
adult
children
reduct
complementari
studi
children
compar
ifa
decreas
oseltamivir
prescript
significantli
higher
adult
filmarrayrp
group
p
compar
adult
manag
ifa
diagnost
yield
significantli
higher
filmarrayrp
ifa
p
median
time
sampl
collect
report
h
min
filmarrayrp
h
ifa
p
conclus
high
respiratori
virus
detect
rate
avail
result
within
two
hour
use
filmarrayrp
associ
decreas
antibiot
prescript
complementari
studi
accur
use
oseltamivir
acut
respiratori
infect
ari
lead
caus
morbid
mortal
worldwid
although
usual
sever
children
elderli
immunocompromis
patient
popul
age
group
suscept
infect
signific
impact
medic
offic
emerg
depart
ed
visit
antimicrobi
prescript
hospit
lost
time
work
school
frequent
agent
respons
ari
respiratori
virus
follow
bacteria
empir
treatment
antibiot
frequent
initi
even
viral
infect
strong
possibl
lead
unnecessari
antibiot
use
direct
diagnosi
respiratori
virus
antigen
detect
use
immunofluoresc
assay
ifa
still
use
typic
limit
eight
virus
rsv
may
lack
sensit
depend
viral
titer
age
time
test
relat
onset
symptom
molecular
method
increas
viral
detect
due
greater
analyt
sensit
compar
convent
method
antigen
detect
andor
viral
cultur
addit
increas
yield
result
detect
respiratori
virus
effect
detect
convent
method
includ
rhinovirus
coronavirus
children
ari
viral
posit
rate
rang
ifa
molecular
method
viral
posit
rate
lower
adult
vari
ifa
molecular
method
new
multiplex
molecular
system
use
close
test
format
significantli
decreas
process
time
filmarray
respiratori
panel
filmarrayrp
salt
lake
citi
ut
detect
pathogen
within
two
hour
need
demonstr
clinic
impact
use
new
rapid
sensit
molecular
assay
prospect
design
studi
aim
studi
determin
time
etiolog
diagnosi
could
impact
medic
manag
relat
antibiot
antivir
prescript
use
complementari
studi
patient
test
either
fimarrayrp
ifa
addit
diagnost
yield
admiss
rate
length
stay
lo
hospit
patient
compar
diagnost
method
perform
prospect
random
nonblind
studi
children
adult
acut
lower
respiratori
infect
alri
attend
ed
centro
de
e
investigacion
cemic
univers
hospit
bueno
air
argentina
two
respiratori
season
aprilnovemb
apriloctob
inclus
criteria
age
month
year
age
children
greater
year
adult
signssymptom
alri
onset
within
preced
day
sign
inform
consent
exclus
criteria
congenit
cardiac
diseas
neurolog
genet
disord
cancer
hiv
immunosuppress
solid
organ
hematopoiet
stem
cell
transplant
studi
approv
cemic
institut
review
board
alri
defin
presenc
least
two
follow
sign
symptom
feverhistori
fever
cough
tachypnea
wheez
difficulti
breath
diffus
focal
sign
auscult
presumpt
diagnosi
bronchiol
influenzalik
ill
ili
bronchiti
laryngotrach
pneumonia
chang
medic
manag
defin
chang
initi
intent
treat
antibiot
oseltamivir
order
complementari
studi
final
decisionaft
test
result
avail
evalu
patient
attend
physician
invit
patient
particip
studi
accept
doctor
document
demograph
data
signssymptom
presumpt
clinic
diagnosi
medic
manag
plan
plan
antibiot
antivir
prescript
complementari
studi
standard
form
moment
physician
obtain
nasopharyng
swab
puritan
usa
place
ml
viral
transport
media
physician
call
laboratori
studi
random
filmarrayrp
ifa
assign
comput
gener
alloc
subject
recruit
monday
friday
pm
april
may
random
ratio
juli
novemb
ratio
could
maintain
staf
constraint
thu
sampl
receiv
pm
process
filmarrayrp
sampl
receiv
outsid
period
process
ifa
random
ratio
return
sampl
assign
filmarrayrp
group
retriev
ed
member
research
team
immedi
process
upon
arriv
virolog
laboratori
sampl
assign
ifa
group
transport
gener
laboratori
subsequ
virolog
laboratori
routin
process
filmarrayrp
detect
virus
rsv
flua
flub
adv
piv
rvev
hmpv
hcov
atyp
bacteria
bordetella
pertussi
mycoplasma
pneumonia
chlamydia
pneumonia
sampl
test
accord
instruct
addit
rehydr
buffer
sampl
rpfilmarray
pouch
perform
biolog
safeti
cabinet
pouch
insert
filmarray
instrument
version
test
time
approxim
min
ifa
indirect
immunofluoresc
assay
specif
monoclon
antibodi
rsv
flua
flub
piv
adv
millipor
chemicon
temecula
ca
take
minimum
h
perform
sampl
batch
assay
perform
per
day
result
report
pm
day
ifa
use
standard
care
children
institut
result
filmarrayrp
ifa
report
telephon
physician
initi
saw
patient
soon
avail
result
also
upload
laboratori
system
moment
physician
question
member
studi
team
chang
medic
manag
antibiot
antivir
therapi
complementari
studi
origin
plan
previous
document
standard
form
final
manag
plan
report
test
result
patient
requir
hospit
inform
lo
oxygen
therapi
icu
stay
mortal
obtain
medic
record
complementari
studi
includ
chest
xray
computer
tomographi
scan
complet
blood
count
urinari
antigen
streptococcu
pneumonia
legionella
pneumonia
bacteri
cultur
blood
urin
sputum
identifi
twofold
differ
medic
chang
confid
power
minimum
sampl
size
requir
fimarrayrp
group
ifa
group
demograph
clinic
characterist
chang
medic
manag
patient
test
filmarrayrp
ifa
compar
use
chisquar
exact
test
categor
variabl
mannwhitneywilcoxon
test
numer
variabl
multivari
analys
use
logist
regress
model
adjust
age
month
children
year
adult
sex
random
use
stata
stata
corp
colleg
station
tx
usa
associ
measur
estim
odd
ratio
associ
confid
interv
ci
p
valu
consid
statist
signific
aprilnovemb
apriloctob
patient
enrol
studi
ten
patient
includ
inadequ
sampl
declin
particip
consent
test
perform
incomplet
form
thu
patient
children
adult
enrol
includ
analysi
demograph
epidemiolog
clinic
characterist
similar
two
group
tabl
children
median
age
month
male
date
mandatori
vaccin
adult
median
age
year
male
older
year
lack
ratio
random
second
portion
result
higher
number
patient
enrol
filmarrayrp
group
test
filmarrayrp
ifa
diagnost
yield
significantli
higher
filmarrayrp
ifa
p
use
filmarrayrp
respiratori
pathogen
detect
children
virus
pneumonia
adult
virus
contrast
use
ifa
respiratori
viru
detect
children
adult
respiratori
pathogen
distribut
children
adult
ifa
filmarrayrp
diagnost
group
shown
fig
percentag
viral
coinfect
filmarrayrp
children
adult
ifa
detect
coinfect
median
transport
time
sampl
collect
ed
arriv
laboratori
min
iqr
filmarrayrp
sampl
min
iqr
ifa
sampl
p
median
time
sampl
collect
result
report
attend
physician
turnaround
time
tat
min
iqr
filmarrayrp
group
h
min
iqr
hour
ifa
group
p
overal
chang
medic
manag
four
time
frequent
filmarrayrp
group
ifa
group
specif
odd
ratio
chang
time
higher
children
p
time
higher
adult
p
tabl
children
chang
associ
decreas
antibiot
complementari
studi
adult
associ
decreas
antibiot
oseltamivir
prescript
univari
multivari
analysi
period
random
ratio
without
random
ratio
second
portion
show
trend
chang
medic
manag
suppl
tabl
b
signific
chang
initi
treatment
plan
final
plan
relat
antibiot
prescript
observ
frequent
children
adult
filmarrayrp
group
versu
ifa
group
respect
p
children
adult
odd
ratio
chang
p
children
p
adult
tabl
chang
antibiot
manag
consist
decid
treat
antibiot
case
virus
detect
diagnost
test
greatest
chang
observ
adult
patient
bronchiti
filmarrayrp
group
versu
ifa
group
p
p
adult
patient
ili
filmarrayrp
group
versu
ifa
group
p
supplement
whole
popul
antibiot
withheld
patient
patient
empir
prescrib
antibiot
contrast
chang
plan
consist
decis
initi
treatment
antibiot
diagnost
test
result
avail
occur
patient
children
test
filmarrayrpon
posit
mycoplasma
pneumonia
filmarrayrp
neg
third
patient
test
ifa
neg
result
adult
test
neg
filmarrayrp
adult
chang
initi
intent
treat
oseltamivir
final
decis
treat
occur
fluab
neg
adult
test
filmarrayrp
versu
fluab
neg
test
ifa
p
hand
chang
consist
decis
treat
oseltamivir
made
diagnost
test
result
avail
observ
fluab
posit
adult
test
filmarrayrp
adult
empir
prescrib
oseltamivir
withheld
filmarrayrp
group
ifa
group
children
oseltamivir
usag
low
signific
chang
treatment
drug
observ
two
studi
group
children
signific
chang
consist
decreas
complementari
studi
observ
filmarrayrp
group
versu
ifa
group
p
ci
p
chang
associ
reduct
order
chest
xray
blood
cell
count
patient
empir
complementari
studi
order
withheld
filmarrayrp
group
adult
chang
order
complementari
studi
either
diagnost
group
among
children
alri
attend
ed
requir
hospit
hospit
rate
lower
children
test
filmarrayrp
ifa
differ
among
adult
alri
attend
ed
requir
hospit
hospit
rate
filmarrayrp
group
ifa
group
p
median
lo
lower
filmarrayrp
group
day
iqr
ifa
group
day
iqr
although
differ
statist
signific
p
six
adult
die
hospit
stay
older
year
old
studi
demonstr
signific
chang
medic
manag
occur
children
adult
result
multiplex
molecular
respiratori
panel
rapidli
avail
physician
ed
compar
patient
manag
use
convent
test
ifa
chang
includ
decreas
antibiot
prescript
children
adult
accur
oseltamivir
treatment
adult
treatment
influenza
posit
patient
treatment
influenzaneg
patient
decreas
complementari
studi
children
decreas
antibiot
prescript
impact
avoid
collater
effect
also
contribut
public
health
effort
combat
increas
antibiot
resist
antibiot
overprescrib
particular
problem
primari
care
virus
caus
respiratori
infect
despit
fact
children
adult
manag
differ
attend
physician
use
differ
treatment
protocol
studi
demonstr
chang
around
decreas
antibiot
prescript
ed
filmarrayrp
result
provid
within
two
hour
studi
evalu
impact
respiratori
viru
diagnosi
relat
antibiot
use
mostli
retrospect
shown
controversi
result
sever
reason
use
convent
realtim
pcr
assay
show
littl
impact
antibiot
use
like
test
result
avail
hour
retrospect
studi
use
filmarrayrp
older
adult
outpati
show
decreas
antibiot
influenzaposit
patient
studi
show
rapid
diagnost
test
influenza
permit
decreas
antibiot
patient
influenzaposit
recent
first
prospect
random
studi
adult
compar
filmarrayrp
convent
pcr
assay
test
publish
uk
although
reduct
antibiot
prescript
observ
decreas
antibiot
dose
singl
dose
brief
coursesless
h
occur
patient
test
filmarrayrp
probabl
due
fact
patient
immedi
start
antibiot
even
test
result
avail
studi
abl
demonstr
chang
medic
manag
relat
reduct
antibiot
prescript
patient
test
filmarrayrp
chang
observ
influenzaposit
patient
also
posit
respiratori
virus
greatest
chang
observ
patient
bronchiti
ili
smallest
decreas
observ
patient
presumpt
pneumonia
posit
viral
diagnosi
could
rule
potenti
coexist
bacteri
infect
brendish
et
al
also
show
littl
chang
antibiot
use
patient
pneumonia
test
filmarrayrp
demonstr
greatest
impact
antibiot
decreas
patient
asthma
acut
exacerb
chronic
obstruct
pulmonari
diseas
relat
oseltamivir
usag
chu
et
al
show
implement
rapid
influenza
pcr
test
associ
decreas
unnecessari
antivir
use
among
adult
inpati
test
neg
influenza
studi
demonstr
signific
decreas
oseltamivir
prescript
adult
influenzaneg
filmarrayrp
hand
increas
oseltamivir
use
observ
patient
test
influenzaposit
permit
initi
appropri
antivir
treatment
within
time
frame
requir
therapeut
efficaci
minim
radiat
exposur
children
becom
increas
prioriti
among
pediatrician
studi
signific
decreas
complementari
studi
children
mostli
chest
xray
occur
diagnosi
avail
time
manner
avoid
unnecessari
irradi
reduct
radiograph
also
observ
studi
impact
rapid
diagnosi
influenza
pediatr
ed
studi
found
trend
toward
reduc
lo
filmarrayrp
group
compar
ifa
group
mean
day
vs
day
children
day
vs
day
adult
result
statist
signific
probabl
due
low
number
patient
requir
hospit
studi
brendish
et
al
found
shorter
mean
lo
patient
test
filmarrayrp
furthermor
patient
posit
filmarrayrp
shortest
length
stay
oneday
lo
reduct
adult
respiratori
infect
repres
minimum
mean
cost
save
approxim
usday
consist
previou
studi
respiratori
infect
associ
cost
perform
children
found
filmarrayrp
high
yield
children
adult
ifa
although
less
sensit
limit
eight
virus
provid
adequ
detect
rsv
flua
piv
children
contrast
detect
rate
classic
virus
lower
adult
probabl
lower
viral
load
respiratori
secret
adult
rapid
test
result
avail
physician
studi
key
factor
determin
chang
medic
practic
perform
studi
routin
clinic
practic
less
assur
rapid
turnaround
time
tat
may
impact
patient
manag
antimicrobi
prescript
recent
prospect
studi
fail
achiev
optimum
tat
due
delay
specimen
process
strength
studi
includ
children
adult
enrol
took
place
two
respiratori
season
studi
demonstr
chang
medic
manag
decreas
antibiot
prescript
popul
studi
limit
singl
center
studi
suffici
power
show
statist
signific
drop
lo
anoth
limit
could
maintain
intend
random
enrol
second
portion
howev
believ
nonrandom
alloc
patient
period
influenc
clinic
behavior
logist
regress
show
statist
signific
effect
studi
period
outcom
summari
prospect
studi
alri
immunocompet
patient
present
ed
use
rapid
multiplex
pcr
respiratori
panel
filmarrayrp
associ
signific
chang
medic
manag
short
tat
sampl
collect
report
result
gave
physician
option
adjust
empir
decis
chang
medic
manag
ed
consult
lead
decreas
antibiot
prescript
complementari
studi
permit
target
use
oseltamivir
work
partial
support
grant
provid
biofir
usa
sponsor
involv
conduct
studi
analysi
data
receiv
speaker
fee
author
report
conflict
interest
